3,9-Diazaspiro[5,5]undecane Amides for Selective Alpha4beta2 NNR Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds targeting α4β2 nicotinic acetylcholine receptors (NNRs) face challenges such as non-selectivity, adverse effects, and potential for receptor desensitization, limiting their therapeutic efficacy in treating cognitive and pain-related disorders.
Innovation Solution
Development of 3,9-diazaspiro[5,5]undecane amide and urea derivatives that act as positive allosteric modulators (PAMs) to selectively enhance α4β2 NNR activity, reducing adverse effects and preventing receptor desensitization, thereby improving therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NNR agonists are used to treat cognitive and pain-related disorders, then therapeutic effects are achieved, but selectivity is poor and adverse effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (3,9-diazaspiro[5,5]undecane core with particular substituents) that confer selective affinity for α4β2 NNRs. The structural modifications at specific positions (R1-R6 groups) create localized interactions that distinguish α4β2 receptors from other NNR subtypes, enabling selective modulation without activating non-target receptors that cause adverse effects
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the compounds (substituent types, positions, and configurations on the diazaspiro core) to optimize selectivity for α4β2 NNRs. By adjusting these chemical parameters, the compounds achieve enhanced binding affinity and selectivity for the target receptor subtype while maintaining therapeutic efficacy and reducing off-target adverse effects
2Reliability
If NNR agonists are used to enhance cognitive function and pain management, then therapeutic benefits are achieved, but receptor desensitization occurs limiting long-term efficacy
Solution Approach 1:
The patent applies inversion by using positive allosteric modulation instead of direct orthosteric agonism. Rather than competing for the endogenous ligand binding site (which causes desensitization), these compounds bind to allosteric sites and enhance the effects of endogenous acetylcholine. This indirect mechanism preserves normal receptor physiology and prevents desensitization, allowing sustained therapeutic benefit without tolerance development
Solution Approach 2:
The patent uses endogenous acetylcholine as an intermediary between the allosteric modulator and the receptor effect. The compounds do not directly activate the receptor but instead bind to allosteric sites and facilitate endogenous acetylcholine binding and receptor activation. This intermediary mechanism maintains natural receptor signaling patterns and prevents the pathological desensitization associated with direct agonist activation
3Object-affected harmful factors
If selective α4β2 NNR modulators are developed to reduce adverse effects, then selectivity is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core 3,9-diazaspiro[5,5]undecane framework providing basic pharmacophore properties, and separate substituent groups (R1-R6) that confer selective affinity for α4β2 NNRs. This modular segmentation allows independent optimization of core stability and peripheral selectivity, managing molecular complexity through functional decomposition
Solution Approach 2:
The patent achieves universality by designing a core diazaspiro structure that provides multiple functions: maintaining structural rigidity, providing nitrogen atoms for hydrogen bonding, and serving as a scaffold for diverse substituent attachment. This multi-functional core reduces the need for additional complex structural elements, achieving selectivity through substituent variation rather than core complexity
Data Source
AI summary
Compounds of formula (I)are useful in treating conditions or disorders ameliorated by α4β2 positive allosteric modulators. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.